Miltefosine, a promising novel agent for schistosomiasis mansoni

International Journal for Parasitology

Volumn 41, Issue 2, 2011, Pages 235-242

  Eissa, Maha M ^a   El Azzouni, Mervat Z ^a   Amer, Eglal I ^a   Baddour, Nahed M ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Histopathological study; Miltefosine; Scanning Electron Microscopy; Schistosoma mansoni; Worm burden

Indexed keywords

METRIFONATE; MILTEFORAN; MILTEFOSINE; PRAZIQUANTEL; UNCLASSIFIED DRUG;

DISEASE CONTROL; DISEASE TREATMENT; DRUG RESISTANCE; HISTOPATHOLOGY; SCANNING ELECTRON MICROSCOPY; SCHISTOSOMIASIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; LIVER GRANULOMA; LIVER SIZE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; RISK REDUCTION; SCANNING ELECTRON MICROSCOPY; SCHISTOSOMIASIS MANSONI;

ANIMALS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; LIVER; MALE; MICE; MICROSCOPY, ELECTRON, SCANNING; PHOSPHORYLCHOLINE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TIME FACTORS;

MUS; SCHISTOSOMA MANSONI;

EID: 79151483904     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2010.09.010     Document Type: Article

References (59)

1. Alonso D., MuÒoz J., Gascòn J., Valls M.E., Corachan M. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am. J. Trop. Med. Hyg. 2006, 74:342-344.
2. Allan D., Payares G., Oward Evans W.H. The phospholipid and fatty acid composition of Schistosoma mansoni and its purified tegumental membrane. Mol. Biochem. Parasitol. 1987, 23:123-128.
3. Azzouz S., Maache M., Dos Santos M.F., Sarciron M.E., Petavy A.F., Osuna A. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani. J. Parasitol. 2006, 92:877-883.
4. Billecocq A. Protection by phospholipids of Schistosoma mansoni schistosomula against action of cytotoxic antibodies and complement. Mol. Biochem. Parasitol. 1987, 25:133-142.
5. Blaha C., Duchêne M., Aspöck H., Walochnik J. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole- resistant and- susceptible strains of Trichomonas vaginalis. J. Antimicrob. Chemother. 2006, 57(2):273-278.
6. Botros S., William S., Hammam O., Zidek Z., Holy A. Activity of 9-(S)-[3- hydroxy-2-(phosphonomethoxy)propyl] adenine against schistosomiasis mansoni in mice. Antimicrob. Agents Chemother. 2003, 47:3853-3858.
7. Botros S., William S., Ebeid F., Cioli D., Katz N., Day T.A., Bennett J.L. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am. J. Trop. Med. Hyg. 2004, 71:206-210.
8. Botros S.S., Bennett J.L. Praziquantel resistance. Expert. Opin. Drug. Dis. 2007, 2:35-40.
9. Botros S.S., William S., Beads J.R., Valiaeva N., Hostetler K.Y. Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro. Antimicrob. Agents Chemother. 2009, 53:5284-5287.
10. Bresiser A., Kim D.J., Fleer E.A., Damenz W., Drube A., Berger M., Nagel G.A., Eibl H., Unger C. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 1987, 22:925-926.
11. Caffrey C.R. Chemotherapy of schistosomiasis: present and future. Curr. Opin. Chem. Biol. 2007, 11:433-439.
12. Choubey V., Maity P., Guha M., Kumar S., Srivastava K., Puri S.K., Bandyopadhyay U. Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism. Antimicrob. Agents Chemother. 2007, 51:696-706.
13. Chugh P., Bradel-Tretheway B., Monteiro-Filho C.M., Vicente P., Sanjay M., Stephen D., Baek K. AKT inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology 2008, 5:11.
14. Doenhoff M.J., Cioli D., Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis. 2008, 21:659-667.
15. Drury R.A.B., Wallington E.A. Carleton Histological Technique 1980, Oxford University Press, Oxford, New York, Toronto. fifth ed.
16. Faghiri Z., Skelly P.J. The role of tegumental aquaporin from the human parasitic worm, Schistosoma mansoni, in osmoregulation and drug uptake. FASEB J. 2009, 23:1-10.
17. Fallon P.G., Doenhoff M.J. Drug- resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. 1994, 51:83-88.
18. Fallon P.G., Fookes R.E., Wharton G.A. Temporal differences in praziquantel- and oxamniquine- induced tegumental damage to adult Schistosoma mansoni: Implication for drug antibody synergy. Parasitology 1996, 112:47-58.
19. Filho A.V.D., Lucas I.C., Sampaio R.N.R. Estudo comparative entre miltefosina oral e antimoniato de N-metil glucamina parenteral no tratamento da leishmaniose experimental causada por Leishmania (Leishmania) amazonensis. Rev. Soc. Bras. Med. Trop. 2008, 41:424-427.
20. Furlong S.T., Caulfield J.P. Schistosoma mansoni: synthesis and release of phospholipids, lysophospholipids, and neutral lipids by schistosomula. Exp. Parasitol. 1989, 69:65-77.
21. Ganguly N.K. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. TDR News WHO 2002, 68:2.
22. Golan D.E., Brown C.S., Cianci C.M., Furlong S.T., Caulfield J.P. Schistosomula of Schistosoma mansoni use lysophosphatidylcholine to lyse adherent human red blood cells and immobilized cell membrane component. J. Cell Biol. 1986, 103:819-828.
23. Gourbal B., Sonuc N., Bhattacharjee H., Legare D., Sundar S., Quellette M., Rosen B.P., Mukhopadhyay R. Drug uptake and modulation of drug resistance in leishmania by aquaglyceroporin. J. Biol. Chem. 2004, 279:31010-31017.
24. Gryseels B., Mbaye D., de Las S.J., Stelma F.F., Guisse F., Van Lieshout L.V., Faye D., Diop M., Ly A., Tchuem-Tchuente L.A., Engels D., Polman K. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med. Int. Healt. 2001, 6:864-873.
25. Hilgard P., Klenner T., Stekar J., Unger C. Alkylphosphocholines, a new class of membrane active anticancer agents. Cancer Chemother. Pharmacol. 1993, 32:90-95.
26. Hopkins A.I., Witty M.J., Owa S. Mission possible. Nature 2007, 449:166-169.
27. Ismail M., Botros S., Metwally A., William S., Farghally A., Tao L., Day T.A., Bennett J.L. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg. 1999, 60:932-935.
28. Keiser, J., Chollet, J., Xiao, S.H., Mei, J.Y., Jiao, P.Y., Utzinger, J., Tanner, M., 2009. Mefloquine - an aminoalcohol with promising antischistosomal properties in mice. PLoS NeglectedTrop. Dis. 3, e350, http://www.plosntds.org.
29. King C.H., Dickman K., Tisch D.J. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005, 365:1561-1569.
30. Lawn S.D., Lucas S.B., Chiodini P.L. Case report: Schistosoma mansoni infection: failure of standard treatment with praziquantel in a returned traveler. Trans. R. Soc. Trop. Med. Hyg. 2003, 97:100-101.
31. López-Arrieta, J., Schneider, L., 2008. Metrifonate for Alzheimer's disease. Cochrane Database of Systematic Reviews (1): CD003155. doi:10.1002/14651858.CD003155.pub3.
32. Lux H., Hart D.T., Parker P.J., Klenner T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkylphospholipid analogues. Adv. Exp. Med. Biol. 1996, 416:201-211.
33. Manneck T., Haggenmuller Y.O., Keiser J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology 2010, 137:85-98.
34. More B., Bhatt H., Kukreja V., Ainapure S.S. Miltefosine, great expectations against visceral leishmaniasis. J. Postgrad. Med. 2003, 49:101-104.
35. Neves J.K., Botelho S.P., de Melo C.M., Pereira V.R., de Lima Mdo C., Pitta Ida R., Albuquerque M.C., Galdino S.L. Biological and immunological activity of new imidazolidines against adult worms of Schistosoma mansoni. Parasitol. Res. 2010, 107:531-538.
36. Postigo M.P., Guido R.V., Oliva G., Castilho M.S., da R Pitta I., de Albuquerque J.F., Andricopulo A.D. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening. J. Chem. Inf. Model. 2010, 50:1-12.
37. Rybczynska M., Spitaler M., Knebel N.G., Boeck G., Grunicke H., Hofmann J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol. 2001, 62:765-772.
38. Sabah A.A., Fletcher C., Webbe G., Doenhoff M.J. Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. 1986, 61:294-303.
39. Seifert K., Duchenne M., Wernsdorfer W.H., Kollaritsch H., Scheiner O., Wiedermann G., Hottokowitz T., Eibl H. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob. Agents Chemother. 2001, 45:1505-1510.
40. Saraiva V.B., Gibaldi D., Previato J.D., Mendonça-previato L., Bozza M.T., Freire-de-Lima C.G., Heise N. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob. Agents Chemother. 2002, 46:3472-3477.
41. Sayed A.A., Simeonov A., Thomas C.J., Inglese J., Austin C.P., Williams D.L. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat. Med. 2008, 14:407-412.
42. Saudi M.N.S., Youssef A.Y., Badr M.H., EL-azzouni M.Z., Mossallam S.F., Baddour N.M., Eissa M.M. Synthesis of subsituted pyrimidinedione derivatives as potential schistosomicidal agents. Lett. Drug Des. Discov. 2009, 6:268-277.
43. Shaw M.K., Erasmus D.A. Schistosoma mansoni: dose related tegumental surface changes after in vivo treatment with praziquantel. Parasitol. Res. 1983, 69:643-653.
44. Shaw M.K., Erasmus D.A. Schistosoma mansoni: structural damage and tegumental repair after in vivo treatment with praziquantel. Parasitology 1987, 94:243-254.
45. Sindermann H., Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 2006, 100(Suppl. 1):S17-S20.
46. Smithers S.R., Terry R.T. Infection of laboratory hosts with cercaria of Schistosoma mansoni and the recovery of adult worms. Parasitology 1965, 55:695-700.
47. Soto J., Toledo J., Gutierrez P., Nicholls R.S., Padilla J., Ángel J., Fischer C., Voss A., Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 2001, 1(33):E57-61.
48. Soto J., Berman J. Treatment of new world cutaneous leishmaniasis with miltefosine. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:S34-S40.
49. Steinmann P., Keiser J., Bos R., Tanner M., Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infec. Dis. 2006, 6:411-425.
50. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Junge K., Bryceson A., Berman J. Oral miltefosine for indian visceral leishmaniasis. N. Engl. J. Med. 2002, 347:1739-1746.
51. Sundar S., Olliaro P.L. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther. Clin. Riskk. Manag. 2007, 3:733-740.
52. Tobinick E.L. The value of drug repositioning in the current pharmaceutical market. Drugs News Pers. 2009, 22:119-125.
53. Urke J.E., Dennis E.A. Phospholipase A2 biochemistry. Cardiovasc. Drug. Ther. 2009, 23:49-59.
54. Walochnik J., Obwaller A., Gruber F., Mildner M., Tschachler E., Suchomel M., Duchene M., Auer H. Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. J. Antimicrob. Chemother. 2009, 64:539-545.
55. World Health Organization (WHO) Prevention and control of schistosomiasis and soil-transmitted helminthiasis; report of a WHO expert committee, Geneva. WHO Technical Report Series 2002, 912:1-57.
56. World Health Organization (WHO) The Global Burden of Disease: Update 2004, World Health Organization, Geneva, Switzerland.
57. World Health Organization (WHO), 2004b. Artemether Protects Against Schistosome Infection. TDR News No. 62.
58. Widmer F., Wright L.C., Obando D., Handke R., Ganendren R., Ellis D.H., Sorrell T.C. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob. Agents Chemother. 2006, 50(2):414-421.
59. Xiao S.H., Binggui S., Chollet J., Utzinger J., Tanner M. Tegumental changes in adult Schistosoma mansoni harbored in mice treated with artemether. J. Parasitol. 2000, 86:1125-1132.